Jazz Pharmaceuticals plc – NASDAQ:JAZZ
Founder-led company
Jazz Pharmaceuticals stock price today
$119.75
-4.84
-3.89%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Jazz Pharmaceuticals stock price monthly change
+18.00%
month
Jazz Pharmaceuticals stock price quarterly change
+18.00%
quarter
Jazz Pharmaceuticals stock price yearly change
+1.78%
year
Jazz Pharmaceuticals key metrics
Market Cap | 7.47B |
Enterprise value | 14.17B |
P/E | -40.51 |
EV/Sales | 3.87 |
EV/EBITDA | 26.49 |
Price/Sales | 2.52 |
Price/Book | 2.99 |
PEG ratio | -1.15 |
EPS | 5.23 |
Revenue | 3.84B |
EBITDA | 1.25B |
Income | 330.79M |
Revenue Q/Q | 1.02% |
Revenue Y/Y | 2.80% |
Profit margin | -6.12% |
Oper. margin | 14% |
Gross margin | 85.23% |
EBIT margin | 14% |
EBITDA margin | 32.61% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeJazz Pharmaceuticals stock price history
Jazz Pharmaceuticals stock forecast
Jazz Pharmaceuticals financial statements
Average Price Target
$182.75
Potential upside: 52.60%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 957.31M | 104.43M | 10.91% |
|---|---|---|---|
| Sep 2023 | 972.14M | 146.82M | 15.1% |
| Dec 2023 | 1.01B | 94.15M | 9.3% |
| Mar 2024 | 901.98M | -14.61M | -1.62% |
| 2022-11-09 | 4.61 | 5.17 |
|---|---|---|
| 2022-12-31 | -12.95066 | -3.8056 |
| 2023-03-01 | -0.15529 | -0.07 |
| Jun 2023 | 11260540000 | 7.73B | 68.69% |
|---|---|---|---|
| Sep 2023 | 11204065000 | 7.71B | 68.86% |
| Dec 2023 | 11393359000 | 7.65B | 67.2% |
| Mar 2024 | 11327075000 | 7.63B | 67.37% |
| Jun 2023 | 296.76M | -85.73M | -96.66M |
|---|---|---|---|
| Sep 2023 | 307.19M | -174.29M | -78.49M |
| Dec 2023 | 167.33M | 101.79M | -100.30M |
| Mar 2024 | 267.22M | -271.90M | -56.55M |
Jazz Pharmaceuticals alternative data
| Aug 2023 | 2,800 |
|---|---|
| Sep 2023 | 2,800 |
| Oct 2023 | 2,800 |
| Nov 2023 | 2,800 |
| Dec 2023 | 2,800 |
| Jan 2024 | 2,800 |
| Feb 2024 | 2,800 |
| Mar 2024 | 2,800 |
| Apr 2024 | 2,800 |
| May 2024 | 2,800 |
| Jun 2024 | 2,800 |
| Jul 2024 | 2,800 |
Jazz Pharmaceuticals other data
58.89%
-35.91%
of JAZZ is owned by hedge funds
326
-112
37.04M
-19.54M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 12000 | 3704 |
| May 2024 | 0 | 5000 |
| Jun 2024 | 0 | 163 |
| Sep 2024 | 0 | 1410 |
| Nov 2024 | 0 | 4700 |
| Dec 2024 | 0 | 2053 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | COZADD BRUCE C director, officer.. | Ordinary Shares | 2,000 | $121.17 | $242,340 | ||
Sale | CARR PATRICIA officer: SVP, Chief Accounting .. | Ordinary Shares | 53 | $122.49 | $6,492 | ||
Sale | PATIL NEENA M officer: EVP & Chief Legal Offi.. | Ordinary Shares | 3,700 | $123.41 | $456,617 | ||
Sale | COZADD BRUCE C director, officer.. | Ordinary Shares | 1,000 | $110.84 | $110,840 | ||
Sale | HENDERSON MARY ELIZABETH officer: SVP, Technical Operati.. | Ordinary Shares | 1,410 | $108.3 | $152,703 | ||
Sale | CARR PATRICIA officer: SVP, Chief Accounting .. | Ordinary Shares | 163 | $108.83 | $17,738 | ||
Sale | PATIL NEENA M officer: EVP & Chief Legal Offi.. | Ordinary Shares | 5,000 | $109.65 | $548,250 | ||
Sale | CARR PATRICIA officer: SVP, Chief Accounting .. | Ordinary Shares | 1,768 | $116.98 | $206,821 | ||
Sale | CARR PATRICIA officer: SVP, Chief Accounting .. | Ordinary Shares | 1,236 | $120.85 | $149,371 | ||
Sale | CARR PATRICIA officer: SVP, Chief Accounting .. | Ordinary Shares | 700 | $117.51 | $82,257 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Stoke Therapeutics: Impressive Pipeline And Big Backers
Amgen: Imdelltra Data And Q1 Results Impress
Jazz Pharmaceuticals: One Step Forward, One Back
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
3 Biotech Stocks With Notable Insider Buying
3 Oversold Biotech Names
Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
-
What's the price of Jazz Pharmaceuticals stock today?
One share of Jazz Pharmaceuticals stock can currently be purchased for approximately $119.75.
-
When is Jazz Pharmaceuticals's next earnings date?
Unfortunately, Jazz Pharmaceuticals's (JAZZ) next earnings date is currently unknown.
-
Does Jazz Pharmaceuticals pay dividends?
No, Jazz Pharmaceuticals does not pay dividends.
-
How much money does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals has a market capitalization of 7.47B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.78% to 3.83B US dollars. Jazz Pharmaceuticals earned 414.83M US dollars in net income (profit) last year or -$0.07 on an earnings per share basis.
-
What is Jazz Pharmaceuticals's stock symbol?
Jazz Pharmaceuticals plc is traded on the NASDAQ under the ticker symbol "JAZZ".
-
What is Jazz Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Jazz Pharmaceuticals?
Shares of Jazz Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Jazz Pharmaceuticals's key executives?
Jazz Pharmaceuticals's management team includes the following people:
- Mr. Bruce C. Cozadd Co-Founder, Chairman & Chief Executive Officer(age: 61, pay: $2,480,000)
- Mr. Daniel N. Swisher Jr. Pres(age: 62, pay: $1,370,000)
- Dr. Robert Iannone M.D. Executive Vice President of R&D and Chief Medical Officer(age: 58, pay: $1,050,000)
- Ms. Renee D. Gala Executive Vice President & Chief Financial Officer(age: 53, pay: $924,520)
- Ms. Kim Sablich Executive Vice President & GM of North America(age: 56, pay: $869,480)
-
Is Jazz Pharmaceuticals founder-led company?
Yes, Jazz Pharmaceuticals is a company led by its founder Mr. Bruce C. Cozadd.
-
How many employees does Jazz Pharmaceuticals have?
As Jul 2024, Jazz Pharmaceuticals employs 2,800 workers.
-
When Jazz Pharmaceuticals went public?
Jazz Pharmaceuticals plc is publicly traded company for more then 18 years since IPO on 1 Jun 2007.
-
What is Jazz Pharmaceuticals's official website?
The official website for Jazz Pharmaceuticals is jazzpharma.com.
-
How can i contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals can be reached via phone at +353 1 634 7800.
-
What is Jazz Pharmaceuticals stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Jazz Pharmaceuticals in the last 12 months, the avarage price target is $182.75. The average price target represents a 52.60% change from the last price of $119.75.
Jazz Pharmaceuticals company profile:
Jazz Pharmaceuticals plc
jazzpharma.comExchange:
NASDAQ
Full time employees:
2,800
Industry:
Biotechnology
Sector:
Healthcare
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Waterloo Exchange
Dublin, 4
Dublin, 4
CIK: 0001232524
ISIN: IE00B4Q5ZN47
CUSIP: G50871105
